Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Merck
Historiska aktiekurser
Aktuell aktiekurs	US$129.56
52 veckors högsta	US$130.29
52 veckors lägsta	US$76.66
Beta	0.20
1 månads förändring	7.26%
3 månaders förändring	8.62%
1 års förändring	60.15%
3 års förändring	17.82%
5 års förändring	67.07%
Förändring sedan börsintroduktionen	11,416.44%

Senaste nyheter och uppdateringar

Seeking Alpha • Jul 02

Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up

Summary Merck & Co., Inc. is fairly valued after a strong YTD rally, with momentum in Keytruda and Winrevair driving raised guidance. Keytruda's patent cliff in 2028 remains a pivotal risk, but MRK is leveraging lifecycle management and pipeline assets to offset erosion. DCF modeling at 4% CAGR and 21% FCF margin supports a Hold rating for MRK stock, with intrinsic value resilient even under moderate downside scenarios. Execution on Winrevair, Keytruda Qlex, and the anti-TL1A IBD asset are critical for sustaining growth and valuation. Read the full article on Seeking Alpha

Uppdatering av berättelse • Jun 30

MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple

Analysts have raised the Merck fair value estimate to $155 from $150, pointing to higher long term earnings expectations and multiple expansion, as reflected in recent Street price target increases to as high as $155. Analyst Commentary Recent Street research on Merck reflects a cluster of constructive views, with several bullish analysts lifting price targets and highlighting long term earnings potential.

Recent updates

Seeking Alpha • Jul 02

Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up

Uppdatering av berättelse • Jun 30

MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple

Uppdatering av berättelse • Jun 15

MRK: Terns Acquisition Execution And Bidding Risk Will Constrain Future Upside

Analysts have nudged their price targets for Merck higher by about $3 to $15 in recent research, supporting a modest increase in the fair value estimate to $101.68. This reflects updated profit margin assumptions and a slightly lower future P/E, along with adjustments to revenue growth expectations and discount rates.

Uppdatering av berättelse • Jun 01

MRK: Oncology Pipeline And Terns Deal Will Shape Future Earnings Balance

Analysts have nudged their average price targets on Merck higher by $3 to $15 in recent weeks, citing updated views on the company’s oncology pipeline, the Terns Pharmaceuticals deal, and specific assets like Sac TMT that some expect could materially influence Merck’s long term earnings profile. Analyst Commentary Recent Street research around Merck clusters around two main themes, the potential of key pipeline assets like Sac TMT and TERN-701, and how recent study outcomes and deal activity could affect execution risk and valuation.

Uppdatering av berättelse • May 21

Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026

Announcement Overview Analyst: Qudus Adebara (Founder, Wane Investment House) Merck & Co., Inc. (“Merck” or “the Company”), known as MSD outside the United States and Canada, has announced that it will present more than 100 abstracts spanning over 25 cancer types at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , scheduled for May 29 – June 2, 2026.

Uppdatering av berättelse • May 19

Merck Completes Acquisition of Terns Pharmaceuticals

Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.

Uppdatering av berättelse • May 17

MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance

Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.

Analysartikel • May 11

Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture

Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...

Uppdatering av berättelse • May 02

MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple

Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.

Uppdatering av berättelse • Apr 19

Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)

Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.

Uppdatering av berättelse • Apr 18

MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple

Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.

Uppdatering av berättelse • Apr 04

MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside

Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.

Uppdatering av berättelse • Mar 21

MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple

The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.

Uppdatering av berättelse • Mar 06

MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside

Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.

Uppdatering av berättelse • Feb 20

MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance

Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.

Uppdatering av berättelse • Feb 06

MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple

Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.

Uppdatering av berättelse • Jan 23

MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance

Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.

Uppdatering av berättelse • Jan 09

MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes

Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.

Uppdatering av berättelse • Dec 24

MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations

Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.

Uppdatering av berättelse • Dec 14

Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs

based on Q3 result

Uppdatering av berättelse • Dec 10

MRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance

Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.

Analysartikel • Dec 02

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...

Uppdatering av berättelse • Nov 26

MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead

Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.

Analysartikel • Nov 02

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Merck & Co., Inc. ( NYSE:MRK ) came out with its quarterly results last week, and we wanted to see how the business is...

Aktieägarnas avkastning

	MRK	US Pharmaceuticals	US Marknad
7D	0.1%	1.4%	1.6%
1Y	60.1%	48.6%	18.6%

Avkastning vs industri: MRK översteg US Pharmaceuticals branschen som gav 48.6 % under det senaste året.

Avkastning vs Marknaden: MRK översteg US marknaden som gav 18.6 % under det senaste året.

Prisvolatilitet

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	4.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Stabil aktiekurs: MRK har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: MRK s veckovolatilitet ( 4% ) har varit stabil under det senaste året.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
1891	74,000	Rob Davis	www.merck.com

Merck & Co, Inc. är ett globalt verksamt hälsovårdsföretag. Företaget erbjuder humanläkemedel inom olika områden under varumärkena Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia och Janumet. Företaget tillhandahåller också veterinärmedicinska läkemedel, vacciner samt lösningar och tjänster för hälsohantering, t.ex. produkter för boskap under varumärkena Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox och Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt; Allflex Livestock Intelligence-lösningar; och produkter för sällskapsdjur under varumärkena Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare och Home Again.

Merck & Co., Inc. Sammanfattning av grunderna

Hur förhåller sig Merck:s resultat och omsättning till dess börsvärde?
MRK grundläggande statistik
Börsvärde	US$319.99b
Vinst(TTM)	US$8.94b
Intäkter(TTM)	US$65.77b

35.8x

P/E-förhållande

4.9x

P/S-förhållande

Är MRK övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
MRK resultaträkning (TTM)
Intäkter	US$65.77b
Kostnad för intäkter	US$15.31b
Bruttovinst	US$50.46b
Övriga kostnader	US$41.53b
Intäkter	US$8.94b

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

Aug 04, 2026

Vinst per aktie (EPS)	3.62
Bruttomarginal	76.73%
Nettovinstmarginal	13.59%
Skuld/egenkapitalförhållande	106.9%

Hur har MRK utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Utdelningar

2.6%

Aktuell utdelningsavkastning

91%

Utbetalningskvot

Ger MRK en tillförlitlig utdelning?

Se MRK utdelningshistorik och jämförelsetal

När behöver man köpa MRK för att få en kommande utdelning?
Merck datum för utdelning
Ex utdelningsdag	Jun 15 2026
Utbetalningsdag för utdelning	Jul 08 2026
Dagar till Ex-utdelning	21 days
Dagar till utdelningsdag	2 days

Ger MRK en tillförlitlig utdelning?

Se MRK utdelningshistorik och jämförelsetal

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/07/06 06:25
Aktiekurs vid dagens slut	2026/07/02 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Merck & Co., Inc. bevakas av 49 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
David Toung	Argus Research Company
Charles Butler	Barclays
Emily Field	Barclays

Merck (MRK) Aktievy

Belöningar

Riskanalys

Analyst Price Targets

US Investments And New Product Launches Will Shape Future Markets

Aging Populations And Biotech Breakthroughs Will Drive Expansion

Global Pricing Pressures Will Erode Margins Amid Rising Regulatory Scrutiny

Top Community Narratives

Merck & Co.: Navigating Pharmaceutical Frontiers Amidst Patent Challenges

Top Community Narratives

Merck & Co.: Navigating Pharmaceutical Frontiers Amidst Patent Challenges

Top Analyst Narratives

US Investments And New Product Launches Will Shape Future Markets

Aging Populations And Biotech Breakthroughs Will Drive Expansion

Global Pricing Pressures Will Erode Margins Amid Rising Regulatory Scrutiny

Merck & Co., Inc. Konkurrenter

Johnson & Johnson

Bristol-Myers Squibb

Pfizer

Eli Lilly

Prishistorik och prestanda

Senaste nyheter och uppdateringar

Merck Reports Positive Tulisokibart Phase 3 Result and Wins New KEYTRUDA Oncology Approvals

Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up

Consensus EPS estimates increase by 21%

US Lawmakers Open National Security Probe Into Merck Clinical Trials in China

MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple

Recent updates

Merck Reports Positive Tulisokibart Phase 3 Result and Wins New KEYTRUDA Oncology Approvals

Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up

Consensus EPS estimates increase by 21%

US Lawmakers Open National Security Probe Into Merck Clinical Trials in China

MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple

Merck Receives European Commission Approval For KEYTRUDA Plus Padcev as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen For Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

FDA Approves KEYTRUDA WELIREG Combo for Early-Stage Renal Cell Carcinoma

Merck Reports Positive Topline Results From The Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active Ulcerative Colitis

Merck Receives U.S. FDA Approval for Expanded Indication of CAPVAXIVE Pneumococcal 21-Valent Conjugate Vaccine in Children and Adolescents Aged 2 Through 17 At Increased Risk for Pneumococcal Disease

MRK: Terns Acquisition Execution And Bidding Risk Will Constrain Future Upside

Merck Receives Fda Approval for KEYTRUDA, KEYTRUDA QLEX, and WELIREG Combinations for Adjuvant Treatment of Clear Cell Renal Cell Carcinoma

Merck Gains FDA Clearance for Kidney Cancer Combo and Expands Poultry Device Business

Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment

Merck Pursues Growth With Terns Deal and Expanding Pipeline as Keytruda Patent Expiry Nears

MRK: Oncology Pipeline And Terns Deal Will Shape Future Earnings Balance

Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation

First quarter dividend of US$0.85 announced

Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2026, Payable on July 8, 2026

Sieben Alexander, P.A. Secures $10.2 Million Verdict for Twin Cities Family Against Cosmetic Talc Manufacturers Vi-Jon and Four Co-Defendants—Gold Bond, Merck (Dr. Scholl's), Johnson & Johnson, and Perrigo Co. of Tennessee

Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer

Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer

Merck Completes Acquisition of Terns Pharmaceuticals

MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026

Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture

Merck & Co., Inc. Updates Earnings Guidance for the Full Year 2026

MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple

New minor risk - Dividend sustainability

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Merck and Eisai Enter Announces FDA Approves Merck’S Once-Daily Idvynso (Doravirine/Islatravir)

Merck Announces FDA Grants Priority Review For Keytruda And Keytruda Qlex Each With Padcev For Cisplatin-Eligible Patients With Muscle-Invasive Bladder Cancer

Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)

MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple

Merck Announces European Commission Approval For Enflonsia (Clesrovimab) For Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Infants

Daiichi Sankyo And Merck Receive Priority Review For Ifinatamab Deruxtecan In Previously Treated Extensive-Stage Small Cell Lung Cancer

Merck & Co., Inc., Annual General Meeting, May 26, 2026

MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside

Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration

Merck Announces Results for Enlicitide Decanoate, an Investigational Oral Pcsk9 Inhibitor

Merck & Co., Inc. Announces Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck Reportedly Nears $6 Billion Deal to Buy Terns Pharma

MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple

Merck Presents New Data Reinforcing Long-Term Efficacy of Gardasil 9 and Gardasil At Eurogin International Multidisciplinary HPV Congress 2026

Upcoming dividend of US$0.85 per share

MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside

Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda

Merck & Co., Inc. Announces KEYTRUDA®? (Pembrolizumab) Plus Padcev®? (enfortumab Vedotin-Ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Ejfv

Merck & Co., Inc. Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL) an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance

Merck Announces Positive New Data for ENFLONSIA (Caresrovimab) for Infants and Children Under 2 Years of Age At Increased Risk for Severe Respiratory Syncytial Virus Disease over Two RSV Seasons